LXRX
HEALTHCARELexicon Pharmaceuticals Inc
$1.60-0.05 (-3.03%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LXRX Today?
No stock-specific AI insight has been generated for LXRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.51$1.95
$1.60
Fundamentals
Market Cap$711M
P/E Ratio—
EPS$-0.14
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding444.1M
LXRX News
24 articles- 5 Best Fast Growing Penny Stocks to Buy Right NowInsider Monkey·May 9, 2026
- Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common sharesStock Titan·May 9, 2026
- [SCHEDULE 13D/A] LEXICON PHARMACEUTICALS, INC. Amended Major Shareholder ReportStock Titan·May 9, 2026
- Lexicon Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surgeInvesting.com Canada·May 7, 2026
- Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1Yahoo Finance·May 7, 2026
- Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesYahoo Finance·May 7, 2026
- Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalYahoo Finance·May 4, 2026
- Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 TrialYahoo Finance·May 3, 2026
- Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851Yahoo Finance·May 1, 2026
- Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- How The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851Yahoo Finance·Apr 27, 2026
- Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin DataYahoo Finance·Apr 23, 2026
- Lexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingGlobeNewswire Inc.·Apr 17, 2026
- How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation AssumptionsYahoo Finance·Apr 7, 2026
- LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity DrugYahoo Finance·Mar 24, 2026
- Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & ExpoYahoo Finance·Mar 24, 2026
- Novo Nordisk (CPSE:NOVO B) Valuation Check As LX9851 Expands Its Obesity Drug PipelineYahoo Finance·Mar 23, 2026
- Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851Yahoo Finance·Mar 23, 2026
- H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)Yahoo Finance·Mar 20, 2026
- H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy RatingYahoo Finance·Mar 12, 2026
- Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for DiabetesYahoo Finance·Mar 11, 2026
- XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures StudyYahoo Finance·Mar 10, 2026
- Lexicon Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
All 24 articles loaded
Price Data
Open$1.66
Previous Close$1.65
Day High$1.66
Day Low$1.60
52 Week High$1.95
52 Week Low$0.51
52-Week Range
$0.51$1.95
$1.60
Fundamentals
Market Cap$711M
P/E Ratio—
EPS$-0.14
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding444.1M
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—